| Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity SV Bardina, P Bunduc, S Tripathi, J Duehr, JJ Frere, JA Brown, ... Science 356 (6334), 175-180, 2017 | 572 | 2017 |
| A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice D Laczkó, MJ Hogan, SA Toulmin, P Hicks, K Lederer, BT Gaudette, ... Immunity 53 (4), 724-732. e7, 2020 | 325 | 2020 |
| A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial R Nachbagauer, J Feser, A Naficy, DI Bernstein, J Guptill, EB Walter, ... Nature medicine 27 (1), 106-114, 2021 | 254 | 2021 |
| A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice AW Freyn, JR da Silva, VC Rosado, CM Bliss, M Pine, BL Mui, YK Tam, ... Molecular Therapy 28 (7), 1569-1584, 2020 | 214 | 2020 |
| Universal influenza virus vaccines and therapeutic antibodies R Nachbagauer, F Krammer Clinical Microbiology and Infection 23 (4), 222-228, 2017 | 202 | 2017 |
| Broadly protective human antibodies that target the active site of influenza virus neuraminidase D Stadlbauer, X Zhu, M McMahon, JS Turner, TJ Wohlbold, AJ Schmitz, ... Science 366 (6464), 499-504, 2019 | 197 | 2019 |
| Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice TJ Wohlbold, R Nachbagauer, H Xu, GS Tan, A Hirsh, KA Brokstad, ... MBio 6 (2), 10.1128/mbio. 02556-14, 2015 | 192 | 2015 |
| Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins R Nachbagauer, A Choi, A Hirsh, I Margine, S Iida, A Barrera, M Ferres, ... Nature immunology 18 (4), 464-473, 2017 | 157 | 2017 |
| Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans R Nachbagauer, TJ Wohlbold, A Hirsh, R Hai, H Sjursen, P Palese, ... Journal of virology 88 (22), 13260-13268, 2014 | 157 | 2014 |
| Novel correlates of protection against pandemic H1N1 influenza A virus infection S Ng, R Nachbagauer, A Balmaseda, D Stadlbauer, S Ojeda, M Patel, ... Nature medicine 25 (6), 962-967, 2019 | 156 | 2019 |
| A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies R Nachbagauer, WC Liu, A Choi, TJ Wohlbold, T Atlas, M Rajendran, ... npj Vaccines 2 (1), 26, 2017 | 132 | 2017 |
| Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial DI Bernstein, J Guptill, A Naficy, R Nachbagauer, F Berlanda-Scorza, ... The lancet infectious diseases 20 (1), 80-91, 2020 | 131 | 2020 |
| Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin M Rajendran, R Nachbagauer, ME Ermler, P Bunduc, F Amanat, R Izikson, ... MBio 8 (2), 10.1128/mbio. 02281-16, 2017 | 127 | 2017 |
| Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans R Nachbagauer, A Choi, R Izikson, MM Cox, P Palese, F Krammer MBio 7 (1), 10.1128/mbio. 01996-15, 2016 | 127 | 2016 |
| Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner CE Mullarkey, MJ Bailey, DA Golubeva, GS Tan, R Nachbagauer, W He, ... MBio 7 (5), 10.1128/mbio. 01624-16, 2016 | 117 | 2016 |
| Is a universal influenza virus vaccine possible? R Nachbagauer, P Palese Annual review of medicine 71, 315-327, 2020 | 115 | 2020 |
| Hemagglutinin stalk immunity reduces influenza virus replication and transmission in ferrets R Nachbagauer, MS Miller, R Hai, AB Ryder, JK Rose, P Palese, ... Journal of virology 90 (6), 3268-3273, 2016 | 92 | 2016 |
| Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses TJ Wohlbold, R Nachbagauer, I Margine, GS Tan, A Hirsh, F Krammer Vaccine 33 (29), 3314-3321, 2015 | 90 | 2015 |
| Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial KV Houser, GL Chen, C Carter, MC Crank, TA Nguyen, MC Burgos Florez, ... Nature medicine 28 (2), 383-391, 2022 | 88 | 2022 |
| Broadly neutralizing antibodies target a haemagglutinin anchor epitope JJ Guthmiller, J Han, HA Utset, L Li, LYL Lan, C Henry, CT Stamper, ... Nature 602 (7896), 314-320, 2022 | 85 | 2022 |
